John G Ullman & Associates Inc. Has $3.29 Million Stake in GSK plc (NYSE:GSK)

John G Ullman & Associates Inc. grew its stake in GSK plc (NYSE:GSK) by 15.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 88,740 shares of the pharmaceutical company’s stock after purchasing an additional 12,160 shares during the period. John G Ullman & Associates Inc.’s holdings in GSK were worth $3,289,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Versant Capital Management Inc grew its position in GSK by 2,816.7% in the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 676 shares during the last quarter. Fairfield Bush & CO. acquired a new stake in shares of GSK during the 2nd quarter valued at about $28,000. BKM Wealth Management LLC acquired a new stake in shares of GSK during the 4th quarter valued at about $32,000. Larson Financial Group LLC boosted its position in shares of GSK by 271.8% during the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 647 shares in the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of GSK by 61.3% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock valued at $42,000 after acquiring an additional 368 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Price Performance

NYSE:GSK traded up $0.48 on Friday, reaching $39.75. The stock had a trading volume of 1,590,960 shares, compared to its average volume of 3,478,990. The company has a market capitalization of $82.38 billion, a P/E ratio of 13.19, a price-to-earnings-growth ratio of 1.82 and a beta of 0.64. GSK plc has a 1-year low of $33.33 and a 1-year high of $43.84. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. The stock has a fifty day moving average price of $41.94 and a 200-day moving average price of $38.77.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). GSK had a return on equity of 51.45% and a net margin of 16.24%. The company had revenue of $10 billion during the quarter, compared to the consensus estimate of $9.79 billion. Research analysts forecast that GSK plc will post 4.01 EPS for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, April 11th. Investors of record on Friday, February 23rd were paid a dividend of $0.3564 per share. This represents a $1.43 dividend on an annualized basis and a dividend yield of 3.59%. This is an increase from GSK’s previous quarterly dividend of $0.34. The ex-dividend date of this dividend was Thursday, February 22nd. GSK’s payout ratio is 52.82%.

Analyst Upgrades and Downgrades

GSK has been the topic of several recent research reports. Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Morgan Stanley started coverage on shares of GSK in a research report on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. Finally, Jefferies Financial Group upgraded shares of GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.